ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation firstwordpharma
January 28, 2019Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen's Humira? biosimilar, Amgevita?, infringes Coherus' U.S. patents -
FDA Approves Udenyca，Udenyca is Coherus’ first drug to receive FDA or EC approval
americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018Coherus BioSciences announced the U.S. Food and Drug Administration (FDA) has approved Udenyca (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppr
Pharma Sources Insight January 2025
